MedTrace Logo

Finerenone Plus SGLT2 Inhibitors in Heart Failure

NCT07351864 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-20

No results posted yet for this study

Summary

The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure.

The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone.

Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.

Conditions

Interventions

DRUG

Finerenone

Finerenone administered orally at a dose of 10 mg once daily.

DRUG

dapagliflozine

Dapagliflozin administered orally at a dose of 10 mg once daily.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Mansour Saad Alqahtani, PhD Candidate · Faculty of pharmacy, Mansoura university

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-18
Primary Completion
2026-04-30
Completion
2026-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07351864 on ClinicalTrials.gov